Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...
Fintel on MSN12h
Wedbush Downgrades Arvinas (ARVN)Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...
Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful ...
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback